BioSpace News Archive

Orthofix Medical Inc. today announced preliminary financial results for the first quarter ended March 31, 2020 and provided a business update.

“Today, the Government of Canada released national-level modelling on the COVID-19 epidemic in Canada. The modelling attempts to show how the epidemic might unfold over the coming months based on our knowledge of how the virus behaves and the potential impact of public health measures.

Three of three abstracts were accepted for presentation at the Annual Meeting of the American Society of Cell and Gene Therapy (ASCGT); The presentations advance the scientific foundation of Enochian’s broad and deep pipeline for potential cures for HIV and Hepatitis B Virus (HBV) infection

DaVita Kidney Care stands with the National Kidney Foundation and its open letter urging hospitals and health systems not to limit care to end stage kidney disease (ESKD) patients with COVID-19 who need life-saving interventions.

Updated Infant Fecal pH Range Identifies Deficiency of Beneficial Bacteria in Infant Gut Microbiome

Silk Medical Aesthetics, Inc., a spin-off of the green chemistry company Evolved By Nature, today announces receipt of FDA IDE approval to initiate a human clinical trial of the industry’s first all-natural, silk-based dermal filler.

PHASE Scientific announces the worldwide commercial launch of the PHASIFY VIRAL RNA Extraction Kit as part of its global effort to help detect and control the COVID-19 disease.

AzurRx BioPharma, Inc. today announced the appointment of Gregory Oakes to the Board of Directors effective April 13, 2020. “Greg is a strong and welcomed addition to our board,” said James Sapirstein, CEO of AzurRx BioPharma. “His broad experience in pharmaceutical commercialization and acqui

What’s New: Intel and the Georgia Institute of Technology announced that they have been selected to lead a Guaranteeing Artificial Intelligence Robustness against Deception program team for the Defense Advanced Research Projects Agency.

The board of directors of Orexo AB has resolved to withdraw the previously communicated proposals to the annual general meeting 2020 concerning the implementation of a new performance-based long-term incentive program for senior executives and key employees within the Orexo group as well as the implementation of a new performance-based long-term incentive program for certain Global Management Team employees and US Leadership Team employees within the Orexo group.